Clinical Trial Update: Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating hypofractionated radiotherapy combined with chemotherapy and camrelizumab as neoadjuvant therapy for pancreatic cancer. Currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: Pancreatic Cancer | Phase 2 | Status: RECRUITING